Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Viking Global and Arbutus Biopharma Corp (ABUS)

Arbutus Biopharma Corp (NASDAQ:ABUS): Andreas Halvorsen’s Viking Global filed an amended 13D.

You can check out Viking Global’s latest holdings and filings here.

Please follow Viking Global (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Viking Global or update its stock holdings.

Andreas Halvorsen
Andreas Halvorsen
Viking Global

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Viking Global Investors 0 0 0 16,013,540 16,013,540 29.1%
Viking Global Performance 0 0 0 16,013,540 16,013,540 29.1%
Viking Global Equities 0 0 0 16,013,540 16,013,540 29.1%
Viking Global Equities II 0 0 0 16,013,540 16,013,540 29.1%
VGE III Portfolio Ltd 0 0 0 16,013,540 16,013,540 29.1%
Viking Long Fund GP 0 0 0 16,013,540 16,013,540 29.1%
Viking Long Fund Master Ltd 0 0 0 16,013,540 16,013,540 29.1%
Viking Global Opportunities GP 0 0 0 16,013,540 16,013,540 29.1%
Viking Global Opportunities Portfolio GP 0 0 0 16,013,540 16,013,540 29.1%
Viking Global Opportunities Illiquid Investments Sub-Master 0 0 0 16,013,540 16,013,540 29.1%
O. Andreas Halvorsen 0 0 0 16,013,540 16,013,540 29.1%
David C. Ott 0 0 0 16,013,540 16,013,540 29.1%
Rose S. Shabet 0 0 0 16,013,540 16,013,540 29.1%
Andreas Halvorsen
Andreas Halvorsen
Viking Global

Page 1 of 17 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13D
(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934

AMENDMENT NO. 3*

Arbutus Biopharma Corporation
(Name of Issuer)
Common Shares, no par value
(Title of Class of Securities)
03879J100
(CUSIP Number)

Eric Komitee

General Counsel

55 Railroad Avenue

Greenwich, Connecticut 06830

203-863-5062

(Name,
Address and Telephone Number of Person

Authorized
to Receive Notices and Communications)

October
16, 2017
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note.
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7
for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 16 Pages)

______________________

* The remainder of this cover page shall be filled
out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 2 of 17 – SEC Filing

CUSIP No. 03879J100 13D Page 2 of 16 Pages
1

NAMES OF REPORTING PERSONS

Viking Global Investors LP

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)
o

(b)
x

3  SEC USE ONLY
4

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

16,013,540

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

16,013,540

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

29.1%*

14

TYPE OF REPORTING PERSON

PN

*

The calculation assumes that there are a total of 55,051,995 Common Shares outstanding as of October 12, 2017,
as reported by Arbutus Biopharma Corporation (the “Issuer”) to Roivant Sciences Ltd. (“Roivant”).
This amount excludes 9,808,386 Common Shares underlying
500,000 shares of the Issuer’s series A participating convertible preferred shares (the “Preferred Shares”)
acquired by Roivant on October 16, 2017, which are not convertible into the Common Shares until they become mandatorily convertible
four years after October 16, 2017 (subject to adjustment and subject to limited exceptions in the event of certain transactions
or fundamental changes that would permit earlier conversion at Roivant’s option).

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 3 of 17 – SEC Filing

CUSIP No. 03879J100 13D Page 3 of 16 Pages
1

NAMES OF REPORTING PERSONS

Viking Global Performance LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)
o

(b)
x

3  SEC USE ONLY
4

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

16,013,540

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

16,013,540

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

29.1%*

14

TYPE OF REPORTING PERSON

OO

*

The calculation assumes that there are a total of 55,051,995 Common Shares outstanding as of October 12, 2017,
as reported by the Issuer to Roivant. This amount excludes
9,808,386 Common Shares underlying 500,000 shares of the Preferred Shares acquired by Roivant on October 16, 2017, which are not
convertible into the Common Shares until they become mandatorily convertible four years after October 16, 2017 (subject to adjustment
and subject to limited exceptions in the event of certain transactions or fundamental changes that would permit earlier conversion
at Roivant’s option).

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 4 of 17 – SEC Filing

CUSIP No. 03879J100 13D Page 4 of 16 Pages
1

NAMES OF REPORTING PERSONS

Viking Global Equities LP

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)
o

(b)
x

3  SEC USE ONLY
4

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

16,013,540

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

16,013,540

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

29.1%*

14

TYPE OF REPORTING PERSON

PN

*

The calculation assumes that there are a total of 55,051,995 Common Shares outstanding as of October 12, 2017,
as reported by the Issuer to Roivant. This amount excludes
9,808,386 Common Shares underlying 500,000 shares of the Preferred Shares acquired by Roivant on October 16, 2017, which are not
convertible into the Common Shares until they become mandatorily convertible four years after October 16, 2017 (subject to adjustment
and subject to limited exceptions in the event of certain transactions or fundamental changes that would permit earlier conversion
at Roivant’s option).

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 5 of 17 – SEC Filing

CUSIP No. 03879J100 13D Page
5 of 16 Pages
1

NAMES OF REPORTING PERSONS

Viking Global Equities II LP

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)
o

(b)
x

3  SEC USE ONLY
4

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

16,013,540

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

16,013,540

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

29.1%*

14

TYPE OF REPORTING PERSON

PN

*

The calculation assumes that there are a total of 55,051,995 Common Shares outstanding as of October 12, 2017,
as reported by the Issuer to Roivant. This amount excludes
9,808,386 Common Shares underlying 500,000 shares of the Preferred Shares acquired by Roivant on October 16, 2017, which are not
convertible into the Common Shares until they become mandatorily convertible four years after October 16, 2017 (subject to adjustment
and subject to limited exceptions in the event of certain transactions or fundamental changes that would permit earlier conversion
at Roivant’s option).

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 6 of 17 – SEC Filing

CUSIP No. 03879J100 13D Page 6 of 16 Pages
1

NAMES OF REPORTING PERSONS

VGE III Portfolio Ltd.

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)
o

(b)
x

3  SEC USE ONLY
4

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

16,013,540

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

16,013,540

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

29.1%*

14

TYPE OF REPORTING PERSON

CO

* The calculation assumes that there are a total of 55,051,995 Common Shares outstanding as of October 12, 2017,
as reported by the Issuer to Roivant. This amount excludes
9,808,386 Common Shares underlying 500,000 shares of the Preferred Shares acquired by Roivant on October 16, 2017, which are not
convertible into the Common Shares until they become mandatorily convertible four years after October 16, 2017 (subject to adjustment
and subject to limited exceptions in the event of certain transactions or fundamental changes that would permit earlier conversion
at Roivant’s option).

 

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 7 of 17 – SEC Filing

CUSIP No. 03879J100 13D Page 7 of 16 Pages
1

NAMES OF REPORTING PERSONS

Viking Long Fund GP LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)
o

(b)
x

3  SEC USE ONLY
4

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

16,013,540

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

16,013,540

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

29.1%*

14

TYPE OF REPORTING PERSON

OO

*

The calculation assumes that there are a total of 55,051,995 Common Shares outstanding as of October 12, 2017,
as reported by the Issuer to Roivant. This amount excludes
9,808,386 Common Shares underlying 500,000 shares of the Preferred Shares acquired by Roivant on October 16, 2017, which are not
convertible into the Common Shares until they become mandatorily convertible four years after October 16, 2017 (subject to adjustment
and subject to limited exceptions in the event of certain transactions or fundamental changes that would permit earlier conversion
at Roivant’s option).

 

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 8 of 17 – SEC Filing

CUSIP No. 03879J100 13D Page 8 of 16 Pages
1

NAMES OF REPORTING PERSONS

Viking Long Fund Master Ltd.

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)
o

(b)
x

3  SEC USE ONLY
4

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

16,013,540

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

16,013,540

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

29.1%*

14

TYPE OF REPORTING PERSON

CO

*

The calculation assumes that there are a total of 55,051,995 Common Shares outstanding as of October 12, 2017,
as reported by the Issuer to Roivant. This amount excludes
9,808,386 Common Shares underlying 500,000 shares of the Preferred Shares acquired by Roivant on October 16, 2017, which are not
convertible into the Common Shares until they become mandatorily convertible four years after October 16, 2017 (subject to adjustment
and subject to limited exceptions in the event of certain transactions or fundamental changes that would permit earlier conversion
at Roivant’s option).

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 9 of 17 – SEC Filing

CUSIP No. 03879J100 13D Page 9 of 16 Pages
1

NAMES OF REPORTING PERSONS

Viking Global Opportunities GP LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)
o

(b)
x

3  SEC USE ONLY
4

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

16,013,540

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

16,013,540

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

29.1%*

14

TYPE OF REPORTING PERSON

OO

*

The calculation assumes that there are a total of 55,051,995 Common Shares outstanding as of October 12, 2017,
as reported by the Issuer to Roivant. This amount excludes
9,808,386 Common Shares underlying 500,000 shares of the Preferred Shares acquired by Roivant on October 16, 2017, which are not
convertible into the Common Shares until they become mandatorily convertible four years after October 16, 2017 (subject to adjustment
and subject to limited exceptions in the event of certain transactions or fundamental changes that would permit earlier conversion
at Roivant’s option).

 

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 10 of 17 – SEC Filing

CUSIP No. 03879J100 13D Page 10 of 16 Pages
1

NAMES OF REPORTING PERSONS

Viking Global Opportunities Portfolio GP LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)
o

(b)
x

3  SEC USE ONLY
4

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

16,013,540

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

16,013,540

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

29.1%*

14

TYPE OF REPORTING PERSON

OO

*

The calculation assumes that there are a total of 55,051,995 Common Shares outstanding as of October 12, 2017,
as reported by the Issuer to Roivant. This amount excludes
9,808,386 Common Shares underlying 500,000 shares of the Preferred Shares acquired by Roivant on October 16, 2017, which are not
convertible into the Common Shares until they become mandatorily convertible four years after October 16, 2017 (subject to adjustment
and subject to limited exceptions in the event of certain transactions or fundamental changes that would permit earlier conversion
at Roivant’s option).

 

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 11 of 17 – SEC Filing

CUSIP No. 03879J100 13D Page 11 of 16 Pages
1

NAMES OF REPORTING PERSONS

Viking Global Opportunities Illiquid Investments Sub-Master
LP

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)
o

(b)
x

3  SEC USE ONLY
4

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

16,013,540

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

16,013,540

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

29.1%*

14

TYPE OF REPORTING PERSON

PN

*

The calculation assumes that there are a total of 55,051,995 Common Shares outstanding as of October 12, 2017,
as reported by the Issuer to Roivant. This amount excludes
9,808,386 Common Shares underlying 500,000 shares of the Preferred Shares acquired by Roivant on October 16, 2017, which are not
convertible into the Common Shares until they become mandatorily convertible four years after October 16, 2017 (subject to adjustment
and subject to limited exceptions in the event of certain transactions or fundamental changes that would permit earlier conversion
at Roivant’s option).

 

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 12 of 17 – SEC Filing

CUSIP No. 03879J100 13D Page 12 of 16 Pages
1

NAMES OF REPORTING PERSONS

O. Andreas Halvorsen

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)
o

(b)
x

3  SEC USE ONLY
4

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Norway

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

16,013,540

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

16,013,540

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

29.1%*

14

TYPE OF REPORTING PERSON

IN

*

The calculation assumes that there are a total of 55,051,995 Common Shares outstanding as of October 12, 2017,
as reported by the Issuer to Roivant. This amount excludes
9,808,386 Common Shares underlying 500,000 shares of the Preferred Shares acquired by Roivant on October 16, 2017, which are not
convertible into the Common Shares until they become mandatorily convertible four years after October 16, 2017 (subject to adjustment
and subject to limited exceptions in the event of certain transactions or fundamental changes that would permit earlier conversion
at Roivant’s option).

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 13 of 17 – SEC Filing

CUSIP No. 03879J100 13D Page
13 of 16 Pages
1

NAMES OF REPORTING PERSONS

David C. Ott

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)
o

(b)
x

3  SEC USE ONLY
4

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

16,013,540

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

16,013,540

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

29.1%*

14

TYPE OF REPORTING PERSON

IN

*

The calculation assumes that there are a total of 55,051,995 Common Shares outstanding as of October 12, 2017,
as reported by the Issuer to Roivant. This amount excludes
9,808,386 Common Shares underlying 500,000 shares of the Preferred Shares acquired by Roivant on October 16, 2017, which are not
convertible into the Common Shares until they become mandatorily convertible four years after October 16, 2017 (subject to adjustment
and subject to limited exceptions in the event of certain transactions or fundamental changes that would permit earlier conversion
at Roivant’s option).

 

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 14 of 17 – SEC Filing

CUSIP No. 03879J100 13D Page 14 of 16 Pages
1

NAMES OF REPORTING PERSONS

Rose S. Shabet

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a) o

(b) x

3  SEC USE ONLY
4

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

16,013,540

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

16,013,540

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

29.1%*

14

TYPE OF REPORTING PERSON

IN

* The calculation assumes that there are a total of 55,051,995 Common Shares outstanding as of October 12, 2017,
as reported by the Issuer to Roivant. This amount excludes
9,808,386 Common Shares underlying 500,000 shares of the Preferred Shares acquired by Roivant on October 16, 2017, which are not
convertible into the Common Shares until they become mandatorily convertible four years after October 16, 2017 (subject to adjustment
and subject to limited exceptions in the event of certain transactions or fundamental changes that would permit earlier conversion
at Roivant’s option).

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 15 of 17 – SEC Filing

This Amendment No. 3 (the “Amendment”)
amends and supplements the Schedule 13D filed by the Reporting Persons on July 13, 2016, as amended and supplemented by Amendment
No. 1 filed on June 14, 2017 and Amendment No. 2 filed on July 6, 2017 (as so amended and supplemented, the “Original
Schedule 13D
”), with respect to the Common Shares of the Issuer. Capitalized terms used in this Amendment and not otherwise
defined shall have the same meanings ascribed to them in the Original Schedule 13D.

Item 4.  Purpose of Transaction

This Amendment amends the Original Schedule
13D to add the following paragraph immediately before the first paragraph of Item 4 of the Original Schedule 13D:

         The
information included in Item 6 is hereby incorporated by reference.

Item 6. Contracts, Arrangements, Understandings or Relationships
with Respect to Securities of the Issuer

 

This Amendment amends the Original Schedule
13D to add the following immediately before the first paragraph of Item 6 of the Original Schedule 13D:

         On
October 16, 2017 (the “First Closing”), pursuant to the subscription agreement, dated as of October 2, 2017,
between the Issuer and Roivant (the “Subscription Agreement”), Roivant acquired an aggregate of 500,000 shares
(the “Initial Preferred Shares”) of the Issuer’s series A participating convertible preferred shares (the
Series A Preferred Shares”) from the Issuer. Additionally, pursuant to the Subscription Agreement, Roivant
will acquire an additional 664,000 Series A Preferred Shares (together with the Initial Preferred Shares, the “Preferred
Shares
”) from the Issuer, following the requisite approval of the shareholders of the Issuer and the satisfaction of
other applicable conditions. The aggregate purchase price of the Preferred Shares is $116.4 million, representing a price per Preferred
Share of $100.00, $50.0 million of which Roivant paid on October 16, 2017 (the “Purchase Price”). The Preferred
Shares will initially be convertible into 22,833,922 Common Shares which conversion will occur mandatorily four years after issuance
(subject to limited exceptions in the event of certain transactions or fundamental changes that would permit earlier conversion
at Roivant’s option).

Pursuant to the Subscription Agreement, on October
16, 2017, the Issuer filed an amendment to the Notice of Articles and the Articles of the Issuer (the “Preferred Shares
Articles Amendment
”). The terms, rights, obligations and preferences of the Preferred Shares are set forth in the Preferred
Shares Articles Amendment.

Preferred Share Rights and Restrictions

Dividends

In the event the Issuer
distributes to all or substantially all holders of Common Shares any cash, shares, evidences of the Issuer’s indebtedness
or other assets, securities or property, including rights to acquire assets, securities or property, the holders of a Preferred
Share will be entitled to receive such dividend in cash (the “Participating Cash Dividend”) or such other distributed
items (a “Participating In-Kind Dividend”) at the same time and in the same manner as holders of Common Shares
would have received if such Preferred Share had been converted into Common Shares upon the Mandatory Conversion Date (as defined
below).

Mandatory Conversion

On the fourth anniversary
of the First Closing (the “Mandatory Conversion Date”), any Preferred Shares not yet converted will be automatically
converted into (i) a number of Common Shares equal to the amount determined by dividing (A) the Purchase Price plus an amount equal
to 8.75% of the Purchase Price per annum, compounded annually (the “Liquidation Preference”) by (B) the conversion
price in effect at the time of conversion; (ii) cash for any accrued but unpaid Participating Cash Dividends (to the extent not
included in the Purchase Price) on the Preferred Shares being converted; and (iii) any accrued and unpaid Participating In-Kind
Dividends.

Optional Conversion

 

Page 15 of 16 Pages

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 16 of 17 – SEC Filing

Each Preferred Share
is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions, recapitalizations,
reclassifications and other transactions by the Issuer on or with respect to the Common Shares, in the event a transaction that
involves (i) a fundamental transfer of value to the Common Shares in which the Preferred Shares do not have the right to participate
or (ii) a Fundamental Change (as defined in the Preferred Shares Articles Amendment), each Preferred Share may be converted prior
to such transaction at the option of its holder into (A) a number of Common Shares equal to the amount determined by dividing (x)
the Liquidation Preference (calculated giving effect to the four-year period set forth in “Mandatory Conversion” above,
irrespective of the date of conversion) by (y) the conversion price in effect at the time of conversion; (B) cash for any accrued
but unpaid Participating Cash Dividends (to the extent not included in the Purchase Price) on the Preferred Shares being converted;
and (C) any accrued and unpaid Participating In-Kind Dividends.

Liquidation Preference; Ranking

In the event of any
liquidation, dissolution or winding up of the Issuer, the holders of the Preferred Shares will be entitled to receive an amount
in cash equal to the amount that the holder of a Preferred Share would have been entitled to receive if such Preferred Share had
been converted into Common Shares upon the Mandatory

Conversion Date. Neither the voluntary
sale, conveyance, exchange or transfer of all or substantially all of the assets of the Issuer nor the consolidation or merger
of the Issuer with or into another entity will be deemed a liquidation, dissolution or winding up of the Issuer.

The Preferred Shares
will rank senior to the Common Shares with respect to any distributions or rights upon liquidation, dissolution or winding up of
the Issuer.

Voting Rights

The Preferred Shares
will not have the right to vote on any matters except as required by law, including under the British Columbia Business Corporations
Act.

The foregoing description
of the Preferred Share Articles Amendment does not purport to be complete and is qualified in its entirety by reference to the
form of the Preferred Share Articles Amendment, which is filed as an exhibit to this Schedule 13D and is incorporated herein by
reference.

 Item 7. Material to Be Filed
as Exhibits

This Amendment amends
and restates Item 7 of the Original Schedule 13D in its entirety as set forth below:

Exhibit 1. Form of Terms Of Series A Participating
Convertible Preferred Stock Of Arbutus Biopharma Corporation, incorporated by reference to Schedule B to Exhibit 7.08 to the Schedule
13D/A of Roivant Sciences Ltd. filed with the Securities and Exchange Commission on October 3, 2017.

Exhibit 99.1 Joint Filing Agreement, dated as of July 5, 2017, among
the Reporting Persons.

Page 16 of 16 Pages

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!

Page 17 of 17 – SEC Filing

SIGNATURE

After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:  October 17, 2017

By:/s/ O. Andreas Halvorsen

By: O. Andreas Halvorsen – individually and as an Executive Committee
Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES LP, VIKING GLOBAL EQUITIES II LP and VGE
III PORTFOLIO LTD., and as an Executive Committee Member of Viking Global Partners LLC, on behalf of VIKING GLOBAL INVESTORS LP,
and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an
Executive Committee Member of VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO
GP LLC and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

By: /s/ David C. Ott

By: David C. Ott – individually and as an Executive Committee Member
of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES LP, VIKING GLOBAL EQUITIES II LP and VGE III PORTFOLIO
LTD., and as an Executive Committee Member of Viking Global Partners LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as Executive
Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee
Member of VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC and VIKING GLOBAL
OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

By: /s/ Rose S. Shabet
By: Rose S. Shabet – individually and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES LP, VIKING GLOBAL EQUITIES II LP and VGE III PORTFOLIO LTD., and as an Executive Committee Member of Viking Global Partners LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

 

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)
Trade (NASDAQ:ABUS) Now!